55513-17-2

Usage

Uses

Used in Pharmaceutical Industry:
1-(3,4-Dichlorobenzyl)piperazine is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in the development of new drugs targeting neurological disorders and mood-related conditions. Its unique structure allows for the creation of novel chemical compounds with diverse therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-(3,4-Dichlorobenzyl)piperazine is utilized as an intermediate in the production of agrochemicals, contributing to the development of effective solutions for pest and disease control in agriculture.
Used in Medicinal Chemistry Research:
1-(3,4-Dichlorobenzyl)piperazine is employed as a valuable building block in medicinal chemistry research, facilitating the design and synthesis of innovative chemical compounds with a wide array of biological activities, thereby expanding the scope of potential treatments and therapies.
Environmental and Toxicological Considerations:
1-(3,4-Dichlorobenzyl)piperazine has been studied for its potential toxicity and environmental impact, emphasizing the necessity for careful handling, use, and disposal to mitigate any adverse effects on human health and the environment.

InChI:InChI=1/C11H14Cl2N2/c12-10-2-1-9(7-11(10)13)8-15-5-3-14-4-6-15/h1-2,7,14H,3-6,8H2

Upstream product

• 110-85-0 piperazine 
• 6287-38-3 3,4-dichlorobenzaldehyde 
• 120-43-4 4-ethoxycarbonylpiperazine 
• 102-47-6 3,4-Dichlorophenylmethyl chloride 
• 18880-04-1 3,4-dichlorobenzyl bromide 
• 1805-32-9 3,4-dichlorobenzyl alcohol 

Downstream Products

• 100389-31-9 4-(3,4-dichloro-benzyl)-piperazine-1-carboxylic acid amide 
• 220772-20-3 1-(S)-[4-(3,4-dichlorobenzyl)piperazin-1-ylcarbonyl]-N-(tert-butoxycarbonyl)-2-methylpropylamine 
• 850923-47-6 1-[4-(3,4-dichlorobenzyl)piperazin-1-ylcarbonyl]-N-(tert-butoxycarbonyl)-2-methylpropylamine 
• 1038547-98-6 (E)-4-(3,4-dichlorophenylmethyl)-1-[3-(3,5-dimethoxy-4-(4-ethoxyphenylmethoxy)phenyl)-1-oxo-2-propenyl]-piperazine 
• 1246541-41-2 (E)-1-[1,4-dioxo-4-phenyl-2-butenyl]-4-(3,4-dichlorophenylmethyl)-piperazine 
• 1038547-92-0 (E)-4-(3,4-dichlorophenyl-methyl)-1-[3-(3,4-di(methoxymethoxy)phenyl)-1-oxo-2-propenyl]-piperazine 
• 1038547-86-2 (E)-4-(3,4-dichlorophenylmethyl)-1-[1-oxo-3-phenyl-2-propenyl]-piperazine 
• 1421322-14-6 C₂₉H₂₇Cl₃N₆O 
• 1383940-00-8 C₂₀H₂₃Cl₃N₂O₂ 
• 1383940-16-6 C₂₀H₂₃Cl₃N₂O₂ 

Relevant academic research and scientific papers

New potent antifungal triazole alcohols containing N-benzylpiperazine carbodithioate moiety: Synthesis, in vitro evaluation and in silico study

A number of 1H-1,2,4-triazole alcohols containing N-(halobenzyl)piperazine carbodithioate moiety have been designed and synthesized as potent antifungal agents. In vitro bioassays against different Candida species including C. albicans, C. glabrata, C. parapsilosis, C. krusei, and C. tropicalis revealed that the N-(4-chlorobenzyl) derivative (6b) with MIC values of 0.063–0.5 μg/mL had the best profile of activity, being 4–32 times more potent than fluconazole. Docking simulation studies confirmed the better fitting of compound 6b in the active site of lanosterol 14α-demethylase (CYP51) enzyme, the main target of azole antifungals. Particularly, the potential of compound 6b against fluconazole-resistant isolates along with its minimal toxicity against human erythrocytes and HepG2 cells make this prototype compound as a good lead for discovery of potent and safe antifungal agents.

Synthesis and bioactive evaluations of novel benzotriazole compounds as potential antimicrobial agents and the interaction with calf thymus DNA

A novel series of benzotriazole derivatives were synthesized and characterized by NMR, IR and MS spectra. The bioactive assay manifested that most of the new compounds exhibited moderate to good antibacterial and antifungal activities against the tested strains in comparison to reference drugs chloromycin, norfloxacin and fluconazole. Especially, 2,4-dichlorophenyl substituted benzotriazole derivative 6f displayed good antibacterial activity against MRSA with MIC value of 4 μg/mL, which was 2-fold more potent than Chloromycin, and it also displayed 3-fold stronger antifungal activity (MIC = 4 μg/mL) than fluconazole (MIC = 16 μg/mL) against Beer yeast. The preliminary interactive investigations of compound 6f with calf thymus DNA revealed that compound 6f could effectively intercalate into DNA to form compound 6f-DNA complex which might block DNA replication to exert antimicrobial activities. Molecular docking experiments suggested that compound 6f projected into base-pairs of DNA hexamer duplex forming two hydrogen bonds with guanine of DNA. The theoretical calculations were in accordance with the experimental results.

Synthesis, biological evaluation, and structure-activity relationship study of novel cytotoxic aza-caffeic acid derivatives

Three series of aza-caffeic acid derivatives with different linkers were designed and synthesized. Each of the synthesized derivatives was then used in cytotoxicity screening on either 8 or 12 human cancer cell lines. The structure-activity relationships on three structural regions A, B, and C are analyzed in detail, indicating that a nine bond linker B, containing a piperazine unit, is the most favorable linker leading to the generation of molecules with potent cytotoxicities. Compound (E)-1-(4-(3,4-dichlorobenzyl) piperazin-1-yl)-3-(4-(4-ethoxybenzyloxy)-3,5-dimethoxyphenyl)prop-2-en-1-one (80) exhibited the most significant and selective cytotoxicity to KB, BEL7404, K562, and Eca109 cell lines, with IC50 values of 0.2, 2.0, 1.7, and 1.1 μM, respectively, stronger than that seen for caffeic acid phenethyl ester (CAPE) and cisplatin (CDDP). Flow cytometric and western blot analysis indicate that compound 80 plays a role in mitochondria-dependent apoptosis activity by suppressing K562 cell proliferation in a concentration- and time-dependent manner.

INHIBITORS OF STEAROYL-COA DESATURASE

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity.

Use of polymer supported reagents for clean multi-step organic synthesis: Preparation of amines and amine derivatives from alcohols for use in compound library generation

The automated sequential application of polymer supported perruthenate (PSP) and polymer supported cyanoborohydride (PSCBH) in an oxidation-reductive amination procedure allowed the efficient transformation of simple alcohols into more complex amines which can be further derivatised by the use of polymer bound amino sulfonylpyridinium chlorides.

2-(substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines

This disclosure describes novel 2-(4-substituted-1-piperazinyl)[1,2,4]triazolo[1,5-a]pyrimidines useful as hypotensive agents.

Pyrazolylpiperazines

This disclosure describes novel pyrazolylpiperazines useful as hypotensive agents in mammals and as intermediates for the preparation of certain pyrazolo[1,5-a]pryrimidines.